{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:57:00Z","timestamp":1753354620838,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41375-021-01497-7","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T02:02:51Z","timestamp":1641434571000},"page":"1180-1184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-0088","authenticated-orcid":false,"given":"Sriram","family":"Ravichandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-5526","authenticated-orcid":false,"given":"Steven","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shameem","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenden","family":"Wisniowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Foard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Martinez-Naharro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7237","authenticated-orcid":false,"given":"Ashutosh D.","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"1497_CR1","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med. 2020;382:1567\u20138.","journal-title":"N Engl J Med"},{"key":"1497_CR2","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"1497_CR3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271\u201380.","journal-title":"Blood"},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1182\/blood-2019-127004","volume":"134","author":"A Godara","year":"2019","unstructured":"Godara A, Toskic D, Rosenthal B, Varga C, Kugelmass A, Zhou P, et al. In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) levels < 10mg\/L are associated with optimal long-term survival. Blood. 2019;134:4369\u20134369.","journal-title":"Blood"},{"key":"1497_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/bmt.2008.180","volume":"42","author":"S Kumar","year":"2008","unstructured":"Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple Myeloma. Bone Marrow Transpl. 2008;42:413\u201320. 2008\/09\/01","journal-title":"Bone Marrow Transpl"},{"key":"1497_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","volume":"32","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple Myeloma but outcomes have improved over time. Leukemia. 2018;32:986\u201395. 2018\/04\/01","journal-title":"Leukemia"},{"key":"1497_CR7","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","volume":"105","author":"J Corre","year":"2020","unstructured":"Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, et al. Early relapse after autologous transplant for Myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105:e480\u2013e483. 06\/05","journal-title":"Haematologica"},{"key":"1497_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.17636","volume":"194","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran S, Cohen Oliver C, Law S, Sachchithanantham S, Mahmood S, Foard D, et al. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data. Br J Haematol. 2021;194:587\u201397.","journal-title":"Br J Haematol"},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317\u201325. 2012\/11\/01","journal-title":"Leukemia"},{"key":"1497_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","volume":"131","author":"G Palladini","year":"2018","unstructured":"Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018;131:525\u201332.","journal-title":"Blood"},{"key":"1497_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4065\/mcp.2010.0480","volume":"86","author":"SK Kumar","year":"2011","unstructured":"Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12\u201318.","journal-title":"Mayo Clin Proc"},{"key":"1497_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","volume":"34","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2020;34:1135\u201343. 2020\/04\/01","journal-title":"Leukemia"},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple Myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208\u201313. 2016\/11\/01","journal-title":"Leukemia"},{"key":"1497_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","volume":"128","author":"T Bochtler","year":"2016","unstructured":"Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128:594\u2013602.","journal-title":"Blood"},{"key":"1497_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46\u201358.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01497-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:13:54Z","timestamp":1649070834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01497-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01497-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ADW has received honoraria from Janssen, GSK, Celgene, and Takeda. The other authors do not have any conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}